FDA Approves Inqovi for Acute Myeloid Leukemia

Follow Drugslib on

By Lori Solomon HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, May 22, 2026 -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or who are ineligible for intensive induction chemotherapy.

The combination of Inqovi plus venetoclax is the first and only oral hypomethylating regimen approved for this population, offering an alternative to parenteral hypomethylating agent-based regimens that require frequent clinic visits.

The approval was based on results from the phase 2 ASCERTAIN-V study, which showed that the combination treatment resulted in 42 patients achieving a complete remission (CR; 41.6 percent), with a median time to CR of two months. The median duration of CR was not reached. Serious adverse reactions occurred in 82 percent of patients who received the combination treatment, including serious adverse reactions of febrile neutropenia (31 percent), sepsis (22 percent), pneumonia (15 percent), bacterial or viral infection (10 percent), hemorrhage (9 percent), and dyspnea (6 percent). Fatal adverse reactions occurred in 8 percent of patients.

"This approval marks an important step forward in expanding how treatment can be delivered for this patient population, offering an all‑oral option that can potentially reduce the overall treatment burden associated with receiving treatment in hospitals or infusion centers," Harold Keer, M.D., Ph.D., the chief medical officer at Taiho Oncology, said in a statement. "We believe this approach has the potential to make a meaningful impact for patients and caregivers."

Approval of Inqovi was granted to Taiho Oncology.

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-23 09:38

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords